BioInteractions re-launches Astute at Compamed
BioInteractions, a UK biomaterial technology company, is re-launching its most Advanced Antithrombogenic coating, Astute.
The non-leaching active antithrombogenic coating, Astute is being targeted at procedures including heart valve replacements, haemodialysis systems, neurological implants and oxygenators where the implant is required to stay in the body for extensive periods of time. Thanks to its clinical recognition for being safe to use on Class 3 blood contacting medical devices, BioInteractions is providing Astute as an answer to serious issues including increasing healthcare associated infections (HAIs) and medical device rejection. BioInteractions will be at COMPAMED 2023, at Hall 8b, stand N20.
Every year, millions of people have regained health because of a medical device implanted in their body, from hip joints to heart valves. However, it is a major concern of the medical industry that human bodies frequently reject implanted devices, and there are no consistently effective strategies to prevent or suppress rejection. This makes the requirement for strategies to improve implants and reduce implant-caused thrombosis even more critical, not only to help resolve these issues but also increase patient safety.
Astute has been developed to improve the haemocompatibility of a device surface by mimicking the endothelial layer. The coating has obtained clinical recognition for its safe and successful use on Class 3 blood contacting medical devices for over 30 years. The multi-action technology confronts clot formation on devices to provide biocompatibility and antithrombogenicity over long periods of time. Astute contains an active component that interrupts the blood cascade mechanism, preventing platelets from activating and hinders thrombus formation. This ensures the blood remains inactive and does not clot further along in the patient. The coating combines this with passive non-thrombogenic elements to prevent deposition and adhesion on the device surface, enhancing the overall antithrombogenic efficacy. Astute uses only non-leaching components, which reduces patient risk and helps the coating to continue performing without reduction in performance over time.
“We understand the significant risks of both device rejection and increasing HAIs to patient safety, which is why we have worked very hard to develop our non-leaching, antithrombogenic coating solution Astute,” explains Arjun Luthra, commercial director, BioInteractions. “Thanks to advances in terms of Astute’s platelet adhesion (prevents 95% of platelet formation) and platelet activation (halts blood cascade mechanism by 92%), we have achieved results of more than 98% reduction in blood clot formation. What this all means is that we have a coating solution that when implemented on an indwelling device, turns it into a permanent implant that has improved performance, therefore enhancing life with an implant, whilst reducing the need for further surgeries and ultimately, improving patient safety.”
BioInteractions will be at Compamed, Hall 8B, stand number N20, showcasing Astute alongside its current portfolio of biocompatible technology solutions including Assist and TridAnt.